Alastair M Buchan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3793133/publications.pdf

Version: 2024-02-01

275	36,515	4955 84	3260 185
papers	citations	h-index	g-index

282	282	282	36931
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Brain health: Key to health, productivity, and wellâ€being. Alzheimer's and Dementia, 2022, 18, 1396-1407.	0.4	27
2	Neuroprotection in Acute Ischemic Stroke: A Brief Review. Canadian Journal of Neurological Sciences, 2022, 49, 741-745.	0.3	9
3	Investigating the temperatureâ€dependent and independent neuroprotective effects of cyclohexyladenosine in SHâ€SY5Y neurons undergoing oxygen glucose deprivation. FASEB Journal, 2022, 36, .	0.2	0
4	Gender parity in scientific authorship in a National Institute for Health Research Biomedical Research Centre: a bibliometric analysis. BMJ Open, 2021, 11, e037935.	0.8	18
5	Circadian Biology and Stroke. Stroke, 2021, 52, 2180-2190.	1.0	38
6	Commentary: Rapalink-1 Increased Infarct Size in Early Cerebral Ischemiaâ€“Reperfusion With Increased Bloodâ€“Brain Barrier Disruption. Frontiers in Physiology, 2021, 12, 761556.	1.3	0
7	A new thrombolytic drug for acute ischaemic stroke. Lancet Neurology, The, 2021, 20, 687-689.	4.9	6
8	Top Priorities for Cerebroprotective Studiesâ€”A Paradigm Shift: Report From STAIR XI. Stroke, 2021, 52, 3063-3071.	1.0	78
9	Growth Differentiation Factor-11 Causes Neurotoxicity During Ischemia in vitro. Frontiers in Neurology, 2020, 11, 1023.	1.1	5
10	Rapamycin Induces an eNOS (Endothelial Nitric Oxide Synthase) Dependent Increase in Brain Collateral Perfusion in Wistar and Spontaneously Hypertensive Rats. Stroke, 2020, 51, 2834-2843.	1.0	18
11	Functional Neurological Disorder. Stroke, 2020, 51, 1629-1635.	1.0	22
12	Effect of Athena SWAN funding incentives on womenâ€™s research leadership. BMJ, The, 2020, 371, m3975.	3.0	29
13	Markers of achievement for assessing and monitoring gender equity in a UK National Institute for Health Research Biomedical Research Centre: A two-factor model. PLoS ONE, 2020, 15, e0239589.	1.1	9
14	The cost of providing mechanical thrombectomy in the UK NHS: a micro-costing study. Clinical Medicine, 2020, 20, e40-e45.	0.8	6
15	Abstract WP151: Rapamycin Improves Post-Recanalization Blood Flow After Acute Experimental Stroke in Rats. Stroke, 2020, 51, .	1.0	0
16	Creating a more supportive and inclusive university culture: a mixed-methods interdisciplinary comparative analysis of medical and social sciences at the University of Oxford. Interdisciplinary Science Reviews, 2019, 44, 166-191.	1.0	30
17	New indicators and indexes for benchmarking universityâ€“industryâ€“government innovation in medical and life science clusters: results from the European FP7 Regions of Knowledge HealthTIES project. Health Research Policy and Systems, 2019, 17, 10.	1.1	8
18	Investigation of the novel mTOR inhibitor AZD2014 in neuronal ischemia. Neuroscience Letters, 2019, 706, 223-230.	1.0	6

#	Article	IF	Citations
19	Rapamycin in ischemic stroke: Old drug, new tricks?. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 20-35.	2.4	38
20	Letter by Harston et al Regarding Article, â€œAlberta Stroke Program Early CT Score Versus Computed Tomographic Perfusion to Predict Functional Outcome After Successful Reperfusion in Acute Ischemic Strokeâ€• Stroke, 2019, 50, STROKEAHA118023749.	1.0	0
21	The effect of rapamycin treatment on cerebral ischemia: A systematic review and meta-analysis of animal model studies. International Journal of Stroke, 2019, 14, 137-145.	2.9	27
22	Structural Transformation to Attain Responsible BIOSciences (STARBIOS2): Protocol for a Horizon 2020 Funded European Multicenter Project to Promote Responsible Research and Innovation. JMIR Research Protocols, 2019, 8, e11745.	0.5	11
23	Complications of endovascular treatment for acute ischemic stroke: Prevention and management. International Journal of Stroke, 2018, 13, 348-361.	2.9	195
24	The role of the endoplasmic reticulum stress response following cerebral ischemia. International Journal of Stroke, 2018, 13, 379-390.	2.9	28
25	Therapeutic Strategies Harnessing Oxidative Stress to Treat Stroke. Oxidative Stress in Applied Basic Research and Clinical Practice, 2017, , 113-133.	0.4	0
26	A Critical Role for Astrocytes in Hypercapnic Vasodilation in Brain. Journal of Neuroscience, 2017, 37, 2403-2414.	1.7	58
27	Closing the gender leadership gap: a multi-centre cross-country comparison of women in management and leadership in academic health centres in the European Union. Human Resources for Health, 2017, 15, 2.	1.1	124
28	Leukoaraiosis, intracerebral hemorrhage, and functional outcome after acute stroke thrombolysis. Neurology, 2017, 88, 638-645.	1.5	84
29	e-ASPECTS software is non-inferior to neuroradiologists in applying the ASPECT score to computed tomography scans of acute ischemic stroke patients. International Journal of Stroke, 2017, 12, 615-622.	2.9	154
30	Neuroprotection in stroke: the importance of collaboration and reproducibility. Brain, 2017, 140, 2079-2092.	3.7	153
31	Inflammatory Stroke Extracellular Vesicles Induce Macrophage Activation. Stroke, 2017, 48, 2292-2296.	1.0	49
32	Circulating endothelial cell-derived extracellular vesicles mediate the acute phase response and sickness behaviour associated with CNS inflammation. Scientific Reports, 2017, 7, 9574.	1.6	43
33	Novel method to study pericyte contractility and responses to ischaemia inÂvitro using electrical impedance. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 2013-2024.	2.4	44
34	Multi-modal assessment of neurovascular coupling during cerebral ischaemia and reperfusion using remote middle cerebral artery occlusion. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 2494-2508.	2.4	11
35	HJM Barnett 1922â€“2016. International Journal of Stroke, 2017, 12, NP3-NP6.	2.9	0
36	Targeting Pericytes and the Microcirculation for Ischemic Stroke Therapy. Springer Series in Translational Stroke Research, 2017, , 537-556.	0.1	3

#	Article	IF	Citations
37	A global call for action to include gender in research impact assessment. Health Research Policy and Systems, 2016, 14, 50.	1.1	89
38	Why do women choose or reject careers in academic medicine? A narrative review of empirical evidence. Lancet, The, 2016, 388, 2948-2958.	6.3	224
39	Markers of achievement for assessing and monitoring gender equity in translational research organisations: a rationale and study protocol. BMJ Open, 2016, 6, e009022.	0.8	23
40	The transient intraluminal filament middle cerebral artery occlusion model as a model of endovascular thrombectomy in stroke. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 363-369.	2.4	66
41	Personalized medical education: Reappraising clinician-scientist training. Science Translational Medicine, 2016, 8, 321fs2.	5.8	31
42	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
43	Leukoaraiosis and lacunes are associated with poor clinical outcomes in ischemic stroke patients treated with intravenous thrombolysis. International Journal of Stroke, 2016, 11, 62-67.	2.9	26
44	A Systematic Review and Meta-Analysis of Randomized Controlled Trials of Endovascular Thrombectomy Compared with Best Medical Treatment for Acute Ischemic Stroke. International Journal of Stroke, 2015, 10, 1168-1178.	2.9	89
45	Robust research: Institutions must do their part for reproducibility. Nature, 2015, 525, 25-27.	13.7	97
46	Medical workforce education and training: A failed decentralisation attempt to reform organisation, financing, and planning in England. Health Policy, 2015, 119, 1545-1549.	1.4	2
47	Reply: Intravenous thrombolysis for ischaemic strokes: a call for reappraisal. Brain, 2015, 138, e342-e342.	3.7	0
48	Organisational culture and post-merger integration in an academic health centre: a mixed-methods study. BMC Health Services Research, 2015, 15, 25.	0.9	23
49	Differential Effects of Paracrine Factors on the Survival of Cells of the Neurovascular Unit during Oxygen Glucose Deprivation. International Journal of Stroke, 2015, 10, 407-414.	2.9	35
50	The future of stroke therapy must not be mired by past arguments. Lancet, The, 2015, 386, 654.	6.3	1
51	Implementation of collaborative governance in cross-sector innovation and education networks: evidence from the National Health Service in England. BMC Health Services Research, 2014, 14, 552.	0.9	23
52	Importance of Preclinical Research in the Development of Neuroprotective Strategies for Ischemic Stroke. JAMA Neurology, 2014, 71, 634.	4.5	52
53	Capillary pericytes regulate cerebral blood flow in health and disease. Nature, 2014, 508, 55-60.	13.7	1,466
54	Improving accountability through alignment: the role of academic health science centres and networks in England. BMC Health Services Research, 2014, 14, 24.	0.9	29

#	Article	IF	Citations
55	The Life of Bo K. SiesjÃ¶, MD, PhD, 1930â€“2013. International Journal of Stroke, 2014, 9, 2-4.	2.9	2
56	Medical education leaders' perceptions of postgraduate medical education reform. Lancet, The, 2014, 384, 306-307.	6.3	3
57	HIF prolyl hydroxylase inhibition prior to transient focal cerebral ischaemia is neuroprotective in mice. Journal of Neurochemistry, 2014, 131, 177-189.	2.1	41
58	Blocked angiogenesis in Galectin-3 null mice does not alter cellular and behavioral recovery after middle cerebral artery occlusion stroke. Neurobiology of Disease, 2014, 63, 155-164.	2.1	28
59	Reply: Thrombolysis in acute ischaemic stroke. Brain, 2014, 137, e282-e282.	3.7	0
60	AM Last Page. Academic Medicine, 2014, 89, 830.	0.8	5
61	A Method of Inducing Global Cerebral Ischemia. Methods in Molecular Biology, 2014, 1135, 111-120.	0.4	2
62	Laser Doppler Flowmetry to Measure Changes in Cerebral Blood Flow. Methods in Molecular Biology, 2014, 1135, 237-248.	0.4	22
63	The exact science of stroke thrombolysis and the quiet art of patient selection. Brain, 2013, 136, 3528-3553.	3.7	68
64	Stroke syndromes and clinical management. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 607-615.	0.2	34
65	Ependymal Ciliary Dysfunction and Reactive Astrocytosis in a Reorganized Subventricular Zone after Stroke. Cerebral Cortex, 2013, 23, 647-659.	1.6	40
66	Tsc1 (hamartin) confers neuroprotection against ischemia by inducing autophagy. Nature Medicine, 2013, 19, 351-357.	15.2	196
67	Alteplase Treatment does not Increase Brain Injury After Mechanical Middle Cerebral Artery Occlusion in the Rat. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, e1-e7.	2.4	19
68	Endogenous Neuroprotection: Hamartin Modulates an Austere Approach to Staying Alive in a Recession. International Journal of Stroke, 2013, 8, 449-450.	2.9	3
69	Tissue Window in Stroke Thrombolysis Study (TWIST): A Safety Study. Canadian Journal of Neurological Sciences, 2013, 40, 17-20.	0.3	21
70	Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke. CNS and Neurological Disorders - Drug Targets, 2013, 12, 155-169.	0.8	42
71	Thrombolytic Agents for Acute Ischaemic Stroke Treatment: The Past, Present and Future. CNS and Neurological Disorders - Drug Targets, 2013, 12, 145-154.	0.8	26
72	Neuroprotection for Stroke: Current Status and Future Perspectives. International Journal of Molecular Sciences, 2012, 13, 11753-11772.	1.8	169

#	Article	IF	Citations
73	Organizational Culture in an Academic Health Center. Academic Medicine, 2012, 87, 709-718.	0.8	36
74	Does the Application of X-Ray Contrast Agents Impair the Clinical Effect of Intravenous Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients?. Stroke, 2012, 43, 1567-1571.	1.0	8
75	The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet, The, 2012, 379, 2352-2363.	6.3	1,018
76	Roles of individual prolylâ€4â€hydroxylase isoforms in the first 24 hours following transient focal cerebral ischaemia: insights from genetically modified mice. Journal of Physiology, 2012, 590, 4079-4091.	1.3	37
77	Microarray analysis of the global gene expression profile following hypothermia and transient focal cerebral ischemia. Neuroscience, 2012, 208, 109-122.	1.1	33
78	Suppression of the inflammatory response by diphenyleneiodonium after transient focal cerebral ischemia. Journal of Neurochemistry, 2012, 123, 98-107.	2.1	17
79	Stroke: management and prevention. Medicine, 2012, 40, 490-499.	0.2	9
80	Assessing research impact in academic clinical medicine: a study using Research Excellence Framework pilot impact indicators. BMC Health Services Research, 2012, 12, 478.	0.9	44
81	Complications of intracerebral haemorrhage. Lancet Neurology, The, 2012, 11, 101-118.	4.9	364
82	Mobile acute stroke units: bringing the hospital to the patient. Lancet Neurology, The, 2012, 11, 382-383.	4.9	6
83	Neuroprotection for Ischaemic Stroke: Translation from the Bench to the Bedside. International Journal of Stroke, 2012, 7, 407-418.	2.9	224
84	Thrombolysis at 3â€“4.5 Hours after Acute Ischemic Stroke Onset â€“ Evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) Registry. Cerebrovascular Diseases, 2011, 31, 223-228.	0.8	87
85	Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. Trials, 2011, 12, 252.	0.7	38
86	Postgraduate medical education in England: 100 years of solitude. Lancet, The, 2011, 378, 1984-1985.	6.3	10
87	Endovascular Stroke Treatment Today. American Journal of Neuroradiology, 2011, 32, 238-243.	1.2	33
88	The timing, extent, progression and regression of deep vein thrombosis in immobile stroke patients: observational data from the CLOTS multicenter randomized trials. Journal of Thrombosis and Haemostasis, 2011, 9, 2193-2200.	1.9	41
89	Cerebral blood flow alteration in neuroprotection following cerebral ischaemia. Journal of Physiology, 2011, 589, 4105-4114.	1.3	43
90	Neuroprotection by Dimethyloxalylglycine following Permanent and Transient Focal Cerebral Ischemia in Rats. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 132-143.	2.4	88

#	Article	IF	Citations
91	Neurological complications of acute ischaemic stroke. Lancet Neurology, The, 2011, 10, 357-371.	4.9	187
92	Final 2 year results of the vascular imaging of acute stroke for identifying predictors of clinical outcome and recurrent ischemic eveNts (VISION) study. BMC Cardiovascular Disorders, 2011, 11, 18.	0.7	23
93	Cellular and Molecular Determinants of Stroke-Induced Changes in Subventricular Zone Cell Migration. Antioxidants and Redox Signaling, 2011, 14, 1877-1888.	2.5	44
94	Therapeutic Manipulation of the HIF Hydroxylases. Antioxidants and Redox Signaling, 2010, 12, 481-501.	2.5	75
95	Assessing the Quality and Reproducibility of a Proteomic Platform for Clinical Stroke Biomarker Discovery. Translational Stroke Research, 2010, 1, 304-314.	2.3	9
96	Stroke: Working toward a Prioritized World Agenda. International Journal of Stroke, 2010, 5, 238-256.	2.9	89
97	Molecular Magnetic Resonance Imaging of Acute Vascular Cell Adhesion Molecule-1 Expression in a Mouse Model of Cerebral Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 1178-1187.	2.4	72
98	The Contribution of L-Arginine to the Neurotoxicity of Recombinant Tissue Plasminogen Activator following Cerebral Ischemia: A Review of rtPA Neurotoxicity. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 1804-1816.	2.4	40
99	Glial and neuronal control of brain blood flow. Nature, 2010, 468, 232-243.	13.7	2,003
100	Preliminary Evidence of a High Risk of Bleeding on Aspirin plus Clopidogrel in Aspirin-NaÃ¯ve Patients in the Acute Phase after TIA or Minor Ischaemic Stroke. Cerebrovascular Diseases, 2010, 29, 460-467.	0.8	24
101	Stroke: Working toward a Prioritized World Agenda. Cerebrovascular Diseases, 2010, 30, 127-147.	0.8	25
102	Organizational Models of Emerging Academic Health Science Centers in England. Academic Medicine, 2010, 85, 1282-1289.	0.8	27
103	Stroke: Working Toward a Prioritized World Agenda. Stroke, 2010, 41, 1084-1099.	1.0	122
104	Outcomes of Thrombolysis for Acute Ischemic Stroke in Octogenarians Versus Nonagenarians. Stroke, 2010, 41, 1833-1835.	1.0	56
105	Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis. New England Journal of Medicine, 2010, 363, 11-23.	13.9	2,634
106	Acute Corticospinal Tract Wallerian Degeneration Is Associated With Stroke Outcome. Stroke, 2010, 41, 751-756.	1.0	97
107	Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet, The, 2010, 375, 1695-1703.	6.3	1,871
108	Ischemic stroke in the elderly: an overview of evidence. Nature Reviews Neurology, 2010, 6, 256-265.	4.9	224

#	Article	IF	Citations
109	Intravenous Thrombolysis for Acute Ischaemic Stroke in Young Adult Patients. Canadian Journal of Neurological Sciences, 2009, 36, 161-167.	0.3	9
110	Should You Thrombolyze All or Any Stroke Patients with Baseline National Institutes of Health Stroke Scale Scores ≤5?. Cerebrovascular Diseases, 2009, 28, 201-202.	0.8	19
111	Admission Hyperglycemia Predicts a Worse Outcome in Stroke Patients Treated With Intravenous Thrombolysis. Diabetes Care, 2009, 32, 617-622.	4.3	172
112	Good Laboratory Practice. Stroke, 2009, 40, 221-3.	1.0	292
113	Good clinical outcome after ischemic stroke with successful revascularization is time-dependent. Neurology, 2009, 73, 1066-1072.	1.5	456
114	Reprint: Good Laboratory Practice: Preventing Introduction of Bias at the Bench. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 221-223.	2.4	62
115	REPRINT: Good Laboratory Practice: Preventing Introduction of Bias at the Bench. International Journal of Stroke, 2009, 4, 3-5.	2.9	25
116	Effects of NXYâ€059 in experimental stroke: an individual animal metaâ€analysis. British Journal of Pharmacology, 2009, 157, 1157-1171.	2.7	111
117	Impact of acute stroke unit on hospital length of stay. Archives of Gerontology and Geriatrics, 2009, 49, e12-e15.	1.4	10
118	The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS). Stroke, 2009, 40, 2769-2775.	1.0	39
119	Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet, The, 2009, 373, 1958-1965.	6.3	414
120	Rapid Evaluation after High-Risk TIA is Associated with Lower Stroke Risk. Canadian Journal of Neurological Sciences, 2009, 36, 450-455.	0.3	22
121	An Improved Scoring System for Identifying Patients at High Early Risk of Stroke and Functional Impairment after an Acute Transient Ischemic Attack or Minor Stroke. International Journal of Stroke, 2008, 3, 3-10.	2.9	110
122	Setting up An Acute Stroke Service. International Journal of Stroke, 2008, 3, 182-187.	2.9	2
123	Interpretation of ESPRIT in the FASTER trial â€“ Authors' reply. Lancet Neurology, The, 2008, 7, 199.	4.9	0
124	Stroke: management and prevention. Medicine, 2008, 36, 592-600.	0.2	6
125	Chapter 59 Approaches to neuroprotective and reperfusion injury therapy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 94, 1205-1223.	1.0	4
126	Therapeutic hypothermia in experimental models of focal and global cerebral ischemia and intracerebral hemorrhage. Expert Review of Neurotherapeutics, 2008, 8, 1255-1268.	1.4	38

#	Article	IF	Citations
127	A case of cocaine-induced basilar artery thrombosis. Nature Clinical Practice Neurology, 2008, 4, 622-626.	2.7	11
128	Stroke in the very old: clinical presentations and outcomes. Age and Ageing, 2008, 37, 473-475.	0.7	18
129	Predicting outcome in hyper-acute stroke: validation of a prognostic model in the Third International Stroke Trial (IST3). Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 397-400.	0.9	37
130	The gender effect in stroke thrombolysis. Neurology, 2008, 71, 1080-1083.	1.5	66
131	Development and efficacy of NXY-059 for the treatment of acute ischemic stroke. Future Neurology, 2008, 3, 229-240.	0.9	10
132	Asymptomatic Hemorrhage After Thrombolysis May Not Be Benign. Stroke, 2007, 38, 75-79.	1.0	169
133	The Interventional Management of Stroke (IMS) II Study. Stroke, 2007, 38, 2127-2135.	1.0	586
134	Strategies for therapy in acute ischemic stroke. Nature Clinical Practice Neurology, 2007, 3, 2-3.	2.7	6
135	Is alteplase safe and effective in routine clinical practice for patients with ischemic stroke?. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 356-357.	3.3	0
136	Kir6.2-containing ATP-sensitive potassium channels protect cortical neurons from ischemic/anoxic injury in vitro and in vivo. Neuroscience, 2007, 144, 1509-1515.	1.1	60
137	Moving Forward with Intra-Arterial and Intravenous Stroke Treatment. International Journal of Stroke, 2007, 2, 45-46.	2.9	1
138	Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurology, The, 2007, 6, 961-969.	4.9	495
139	Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 826-829.	0.9	147
140	Neuroprotection and neurogenesis: Modulation of cornus ammonis 1 neuronal survival after transient forebrain ischemia by prior fimbria-fornix deafferentation. Neuroscience, 2006, 140, 219-226.	1.1	8
141	Translational vehicles for neuroprotection. Biochemical Society Transactions, 2006, 34, 1318-1322.	1.6	6
142	MR Angiography Compared to Conventional Selective Angiography in Acute Stroke. Canadian Journal of Neurological Sciences, 2006, 33, 58-62.	0.3	35
143	NXY-059. Stroke, 2006, 37, 2189-2190.	1.0	21
144	Prior deafferentation confers long term protection to CA1 against transient forebrain ischemia and sustains GluR2 expression. Brain Research, 2006, 1075, 201-212.	1.1	4

#	Article	IF	Citations
145	Improved regional cerebral blood flow is important for the protection seen in a mouse model of late phase ischemic preconditioning. Brain Research, 2006, 1121, 231-237.	1.1	49
146	Recent advances in management of transient ischaemic attacks and minor ischaemic strokes. Lancet Neurology, The, 2006, 5, 323-331.	4.9	153
147	Imaging of acute stroke. Lancet Neurology, The, 2006, 5, 755-768.	4.9	311
148	Diabetes, leukoencephalopathy and rage. Neurobiology of Disease, 2006, 23, 445-461.	2.1	91
149	The ALIAS Pilot Trial. Stroke, 2006, 37, 2100-2106.	1.0	135
150	The ALIAS Pilot Trial. Stroke, 2006, 37, 2107-2114.	1.0	123
151	Sex-Based Differences in the Effect of Intra-Arterial Treatment of Stroke. Stroke, 2006, 37, 2322-2325.	1.0	82
152	Clarification. Stroke, 2006, 37, 2648-2648.	1.0	4
153	Serotonin Transporter Gene Promoter Region Polymorphism Associated With Poststroke Major Depression. Journal of Neuropsychiatry and Clinical Neurosciences, 2006, 18, 96-99.	0.9	56
154	How well does ASPECTS predict the outcome of acute stroke treated with IV tPA?. Neurology, 2006, 67, 516-518.	1.5	55
155	Insular cortical ischaemia does not independently predict acute hypertension or hyperglycaemia within 3 h of onset. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 885-887.	0.9	9
156	Informed Consent for Thrombolytic Therapy in Acute Ischemic Stroke. Stroke, 2005, 36, 528-529.	1.0	3
157	Use of Magnetic Resonance Imaging in Predicting Further Vascular Events Among Patients With Transient Ischemic Attacks. Stroke, 2005, 36, 526-528.	1.0	0
158	Stroke prevention. Postgraduate Medicine, 2005, 117, 26-30.	0.9	5
159	Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke. Stroke, 2005, 36, 880-890.	1.0	176
160	A Novel Method to Derive Separate Gray and White Matter Cerebral Blood Flow Measures from MR Imaging of Acute Ischemic Stroke Patients. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 1236-1243.	2.4	23
161	Triaging transient ischemic attack and minor stroke patients using acute magnetic resonance imaging. Annals of Neurology, 2005, 57, 848-854.	2.8	223
162	A study of the workload and effectiveness of a comprehensive acute stroke service. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 863-865.	0.9	36

#	Article	IF	Citations
163	Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. Cmaj, 2005, 172, 1307-1312.	0.9	396
164	C-EPO: Ready for Prime-Time Preconditioning?. Cerebrovascular Diseases, 2005, 19, 272-273.	0.8	11
165	Statins Are Associated With Better Outcomes After Carotid Endarterectomy in Symptomatic Patients. Stroke, 2005, 36, 2072-2076.	1.0	188
166	Early T1- and T2-weighted MRI signatures of transient and permanent middle cerebral artery occlusion in a murine stroke model studied at 9.4T. Neuroscience Letters, 2005, 388, 54-59.	1.0	53
167	Improved regional cerebral blood flow mediates tolerance afforded by ischemic preconditioning. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S298-S298.	2.4	0
168	The Rise and Fall of NMDA Antagonists for Ischemic Stroke. Current Molecular Medicine, 2004, 4, 131-136.	0.6	179
169	Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years old with acute ischaemic stroke? - The Calgary experience. Age and Ageing, 2004, 33, 143-149.	0.7	52
170	Mild Neurological Symptoms Despite Middle Cerebral Artery Occlusion. Stroke, 2004, 35, 469-471.	1.0	20
171	ASPECTS on CTA Source Images Versus Unenhanced CT. Stroke, 2004, 35, 2472-2476.	1.0	173
172	Predicting Functional Outcome After Intra-Arterial Thrombolysis: Aspects of ASPECTS. Stroke, 2004, 35, e7-8; author reply e7-8.	1.0	2
173	Acute Neurovascular Syndromes: Hurry Up, Please, Itâ€™s Time 1. Stroke, 2004, 35, 360-362.	1.0	6
174	Interobserver Variation of ASPECTS in Real Time. Stroke, 2004, 35, e103-5.	1.0	82
175	Temperature-Regulated Model of Focal Ischemia in the Mouse. Stroke, 2004, 35, 1720-1725.	1.0	83
176	The probability of middle cerebral artery MRA flow signal abnormality with quantified CT ischaemic change: targets for future therapeutic studies. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1426-1430.	0.9	31
177	The Neurotoxicity of Tissue Plasminogen Activator?. Journal of Cerebral Blood Flow and Metabolism, 2004, 24, 945-963.	2.4	241
178	Organization of regional and local stroke resources: Methods to expedite acute management of stroke. Current Neurology and Neuroscience Reports, 2004, 4, 13-18.	2.0	6
179	MR molecular imaging of early endothelial activation in focal ischemia. Annals of Neurology, 2004, 56, 116-120.	2.8	86
180	Mechanisms of Hemorrhagic Transformation After Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke. Stroke, 2004, 35, 2726-2730.	1.0	294

#	Article	IF	Citations
181	Combined Intravenous and Intra-Arterial Recanalization for Acute Ischemic Stroke: The Interventional Management of Stroke Study. Stroke, 2004, 35, 904-911.	1.0	676
182	Lost in translation: taking neuroprotection from animal models to clinical trials. Experimental Neurology, 2004, 188, 200-204.	2.0	88
183	World Stroke Day. Stroke, 2004, 35, 1241-1241.	1.0	0
184	Early risk of stroke after a transient ischemic attack in patients with internal carotid artery disease. Cmaj, 2004, 170, 1105-1109.	0.9	207
185	Fluid-attenuated inversion recovery preparation: not an improvement over conventional diffusion-weighted imaging at 3T in acute ischemic stroke. American Journal of Neuroradiology, 2004, 25, 1653-8.	1.2	13
186	Hyperacute stroke: experience essential when reading unenhanced CT scans. American Journal of Neuroradiology, 2004, 25, 516; author reply 516-8.	1.2	0
187	Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN). Stroke, 2003, 34, 2543-2548.	1.0	416
188	Hypothermia rescues hippocampal CA1 neurons and attenuates down-regulation of the AMPA receptor GluR2 subunit after forebrain ischemia. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2906-2910.	3.3	106
189	Reliability of Assessing Percentage of Diffusion-Perfusion Mismatch. Stroke, 2003, 34, 1681-1683.	1.0	98
190	Selection of Acute Ischemic Stroke Patients for Intra-Arterial Thrombolysis With Pro-Urokinase by Using ASPECTS. Stroke, 2003, 34, 1925-1931.	1.0	262
191	ASPECTS Reading Requires Training and Experience. Stroke, 2003, 34, e179; author reply e179.	1.0	22
192	Lessons in experimental ischemia for clinical stroke medicine. Current Opinion in Neurology, 2003, 16, 65-71.	1.8	9
193	CP-465,022, a Selective Noncompetitive AMPA Receptor Antagonist, Blocks AMPA Receptors but Is Not Neuroprotective In Vivo. Stroke, 2003, 34, 171-176.	1.0	26
194	Ever Decreasing Circles: Advances in Antiplatelet Therapy and Anticoagulation. Stroke, 2003, 34, 348-350.	1.0	1
195	Neuroprotective Stroke Trials: A Ten Year Dry Season. , 2003, , 236-251.		0
196	The relative importance of barriers to the prescription of warfarin for nonvalvular atrial fibrillation. Canadian Journal of Cardiology, 2003, 19, 280-4.	0.8	39
197	Biochemistry of ischemic stroke. Advances in Neurology, 2003, 92, 151-64.	0.8	22
198	Lessons in experimental ischemia for clinical stroke medicine. Current Opinion in Neurology, 2003, 16, 65-71.	1.8	4

#	Article	IF	Citations
199	Markers of Increased Risk of Intracerebral Hemorrhage After Intravenous Recombinant Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke in Clinical Practice. Circulation, 2002, 105, 1679-1685.	1.6	394
200	Acute Intravenousâ€“Intra-Arterial Revascularization Therapy for Severe Ischemic Stroke. Stroke, 2002, 33, 279-282.	1.0	81
201	Understanding and managing ischemic stroke. Canadian Journal of Physiology and Pharmacology, 2001, 79, 283-296.	0.7	32
202	Thrombolytic Therapy for Acute Ischemic Stroke: The CAEP Position Statement: another perspective. Canadian Journal of Emergency Medicine, 2001, 3, 180-182.	0.5	0
203	Methodology for the Canadian Activase for Stroke Effectiveness Study (CASES). Canadian Journal of Neurological Sciences, 2001, 28, 232-238.	0.3	49
204	Cerebral Ischemia: Molecular and Cellular Pathophysiology. 1st Edition. 1999. Edited by Wolfgang Walz. Published by Humana Press Inc. 278 pages. C$181.25 approx.. Canadian Journal of Neurological Sciences, 2001, 28, 380-380.	0.3	0
205	Aspects of Stroke Imaging. Canadian Journal of Neurological Sciences, 2001, 28, 99-100.	0.3	12
206	Hyperdense Sylvian Fissure MCA â€œDotâ€•Sign. Stroke, 2001, 32, 84-88.	1.0	160
207	Dehydroepiandrosterone (DHEA) reduces neuronal injury in a rat model of global cerebral ischemia. Brain Research, 2001, 888, 263-266.	1.1	65
208	NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. Brain Research, 2001, 909, 46-50.	1.1	100
209	Symptomatic hemorrhage after alteplase therapy not due to silent ischemia. BMC Neurology, 2001, 1, 1.	0.8	11
210	The Canadian Activase for Stroke Effectiveness Study (CASES): Interim Results. Stroke, 2001, 32, 323-323.	1.0	5
211	Neuroprotection achieved with a novel proteasome inhibitor which blocks NF-ÎºB activation. NeuroReport, 2000, 11, 427-430.	0.6	42
212	Caspase Inhibitors Reduce Neuronal Injury After Focal but Not Global Cerebral Ischemia in Rats. Stroke, 2000, 31, 176-182.	1.0	141
213	Doubts, Fears and Misconceptions. What is the Future of Thrombolysis in Acute Stroke?. Canadian Journal of Neurological Sciences, 2000, 27, 283-287.	0.3	4
214	Prolonged but Delayed Postischemic Hypothermia: A Long-term Outcome Study in the Rat Middle Cerebral Artery Occlusion Model. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 1702-1708.	2.4	210
215	CoQ10 fails to protect brain against focal and global ischemia in rats. Brain Research, 2000, 877, 7-11.	1.1	15
216	Animal models. British Medical Bulletin, 2000, 56, 307-317.	2.7	50

#	Article	IF	Citations
217	The Imperative to Develop Dedicated Stroke Centers. JAMA - Journal of the American Medical Association, 2000, 283, 3125.	3.8	17
218	Intra-arterial thrombolysis for hyperacute stroke. Lancet, The, 2000, 356, 1112.	6.3	0
219	Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Lancet, The, 2000, 355, 1670-1674.	6.3	2,082
220	Apoptosis After Experimental Stroke: Fact or Fashion?. Journal of Neurotrauma, 2000, 17, 899-914.	1.7	133
221	PREDICTORS OF STROKE OUTCOME. Neurologic Clinics, 2000, 18, 455-473.	0.8	41
222	Can pure oxygen prevent stroke damage?. Critical Care Medicine, 2000, 28, 3101-3102.	0.4	1
223	Continuing Postischemic Neuronal Death in CA1. Stroke, 1999, 30, 662-668.	1.0	166
224	Tissue plasminogen activator does not increase neuronal damage in rat models of global and focal ischemia. Neurology, 1999, 52, 1381-1381.	1.5	52
225	Indefatigable CA1 Sector Neuroprotection with Mild Hypothermia Induced 6 Hours after Severe Forebrain Ischemia in Rats. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 742-749.	2.4	210
226	Biology of ischemic cerebral cell death. Progress in Cardiovascular Diseases, 1999, 42, 185-207.	1.6	102
227	Serum Glucose Level and Diabetes Predict Tissue Plasminogen Activatorâ€“Related Intracerebral Hemorrhage in Acute Ischemic Stroke. Stroke, 1999, 30, 34-39.	1.0	355
228	Correlation of Neurologic Dysfunction with CT Findings in Early Acute Stroke. Canadian Journal of Neurological Sciences, 1999, 26, 182-189.	0.3	15
229	Biphasic Opening of the Blood-Brain Barrier Following Transient Focal Ischemia: Effects of Hypothermia. Canadian Journal of Neurological Sciences, 1999, 26, 298-304.	0.3	210
230	Comparison of the Changes in Protein Kinase C Induced by Glutamate in Primary Cortical Neurons and by in Vivo Cerebral Ischaemia. Cellular Signalling, 1998, 10, 291-295.	1.7	24
231	Brain derived neurotrophic factor induction of N-methyl-D-aspartate receptor subunit NR2A expression in cultured rat cortical neurons. Neuroscience Letters, 1998, 252, 211-214.	1.0	49
232	Canadian Guidelines for Intravenous Thrombolytic Treatment in Acute Stroke: A Consensus Statement of The Canadian Stroke Consortium. Canadian Journal of Neurological Sciences, 1998, 25, 257-259.	0.3	49
233	Exploration of P-type Ca 2+ Channels as Drug Targets for the Treatment of Epilepsy or Ischemic Stroke. Neuropharmacology, 1997, 36, 107-113.	2.0	19
234	Alteration in NMDA receptor subunit mRNA expression in vulnerable and resistant regions of in vitro ischemic rat hippocampal slices. Neuroscience Letters, 1997, 232, 87-90.	1.0	28

#	Article	IF	Citations
235	Identification of calcium channels involved in neuronal injury in rat hippocampal slices subjected to oxygen and glucose deprivation. Brain Research, 1997, 753, 209-218.	1.1	48
236	Effect of temperature in focal ischemia of rat brain studied by31P and1H spectroscopic imaging. Magnetic Resonance in Medicine, 1997, 37, 346-354.	1.9	16
237	Mechanisms of 1S,3R-ACPD-induced neuroprotection in rat hippocampal slices subjected to oxygen and glucose deprivation. Neuropharmacology, 1996, 35, 1037-1048.	2.0	25
238	Mechanisms of cerebral ischemia: Intracellular cascades and therapeutic interventions. Journal of Cardiothoracic and Vascular Anesthesia, 1996, 10, 139-146.	0.6	44
239	Chapter 7 NMDA Antagonists: Their Role in Neuroprotection. International Review of Neurobiology, 1996, 40, 137-171.	0.9	33
240	An Early Loss in Membrane Protein Kinase C Activity Precedes the Excitatory Amino Acidâ€induced Death of Primary Cortical Neurons. Journal of Neurochemistry, 1996, 66, 951-962.	2.1	49
241	Neuroprotective effects of Ï‰-Aga-IVA against in vitro ischaemia in the rat hippocampal slice. NeuroReport, 1995, 6, 1617-1620.	0.6	31
242	Lack of Effect of Aspirin in Asymptomatic Patients with Carotid Bruits and Substantial Carotid Narrowing. Annals of Internal Medicine, 1995, 123, 649.	2.0	128
243	Differences in DNA Fragmentation following Transient Cerebral or Decapitation Ischemia in Rats. Journal of Cerebral Blood Flow and Metabolism, 1995, 15, 728-737.	2.4	117
244	A randomized study of the influence of perfusion technique and pH management strategy in 316 patients undergoing coronary artery bypass surgery:. Journal of Thoracic and Cardiovascular Surgery, 1995, 110, 349-362.	0.4	316
245	A Selective N-Type Ca²⁺-Channel Blocker Prevents CA1 Injury 24 h following Severe Forebrain Ischemia and Reduces Infarction following Focal Ischemia. Journal of Cerebral Blood Flow and Metabolism, 1994, 14, 903-910.	2.4	136
246	Delayed Treatment with AMPA, but Not NMDA, Antagonists Reduces Neocortical Infarction. Journal of Cerebral Blood Flow and Metabolism, 1994, 14, 251-261.	2.4	166
247	In vivo Binding of [3H]Nimodipine in Rat Brain after Transient Forebrain Ischemia. Journal of Cerebral Blood Flow and Metabolism, 1994, 14, 397-405.	2.4	11
248	Failure to prevent selective CA1 neuronal death and reduce cortical infarction following cerebral ischemia with inhibition of nitric oxide synthase. Neuroscience, 1994, 61, 1-11.	1.1	42
249	DNA damage consistent with apoptosis in transient focal ischaemic neocortex. NeuroReport, 1994, 5, 493-496.	0.6	196
250	Treatment with an AMPA Antagonist 12 Hours following Severe Normothermic Forebrain Ischemia Prevents CA₁ Neuronal Injury. Journal of Cerebral Blood Flow and Metabolism, 1993, 13, 933-939.	2.4	150
251	Global ischemia can cause DNA fragmentation indicative of apoptosis in rat brain. Neuroscience Letters, 1993, 164, 89-92.	1.0	484
252	Chapter 8 Antagonism of the NMDA and non-NMDA receptors in global versus focal brain ischemia. Progress in Brain Research, 1993, 96, 125-135.	0.9	51

#	Article	IF	Citations
253	Sciatic Neuropathy Associated With Persistent Sciatic Artery. Archives of Neurology, 1992, 49, 967-968.	4.9	21
254	Do NMDA Antagonists Prevent Neuronal Injury? No.. Archives of Neurology, 1992, 49, 420-421.	4.9	32
255	A new model of temporary focal neocortical ischemia in the rat.. Stroke, 1992, 23, 273-279.	1.0	218
256	Tirilazad reduces cortical infarction after transient but not permanent focal cerebral ischemia in rats.. Stroke, 1992, 23, 894-899.	1.0	149
257	Hypothermia but not NMDA Receptor Antagonist MK-801 Attenuates Neuron Damage. Journal of Neurosurgical Anesthesiology, 1992, 4, 222-223.	0.6	0
258	The effect of the NMDA receptor antagonist MK-801 on cerebral blood flow and infarct volume in experimental focal stroke. Brain Research, 1992, 574, 171-177.	1.1	134
259	Immediate or delayed mild hypothermia prevents focal cerebral infarction. Brain Research, 1992, 587, 66-72.	1.1	177
260	Advances in Cerebral Ischemia: Experimental Approaches. Neurologic Clinics, 1992, 10, 49-61.	0.8	47
261	Failure of the Lipid Peroxidation Inhibitor, U74006F, to Prevent Postischemic Selective Neuronal Injury. Journal of Cerebral Blood Flow and Metabolism, 1992, 12, 250-256.	2.4	32
262	Blockade of the AMPA receptor prevents CA1 hippocampal injury following severe but transient forebrain ischemia in adult rats. Neuroscience Letters, 1991, 132, 255-258.	1.0	251
263	Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia. NeuroReport, 1991, 2, 473-476.	0.6	131
264	N-Methyl-D-Aspartate Excitotoxicity: Is It Important in Ischemic Neuronal Injury?. , 1991, , 59-75.		0
265	Septo-hippocampal deafferentation protects CA1 neurons against ischemic injury. Brain Research, 1990, 512, 7-14.	1.1	60
266	The four-vessel occlusion rat model: method for complete occlusion of vertebral arteries and control of collateral circulation.. Stroke, 1988, 19, 913-914.	1.0	234
267	Intraluminal thrombus in the cerebral circulation. Implications for surgical management.. Stroke, 1988, 19, 681-687.	1.0	111
268	Intraluminal thrombus of the internal carotid arteries: angiographic demonstration of resolution with anticoagulant therapy alone.. Radiology, 1986, 160, 369-373.	3.6	42
269	Septal elicitation of hippocampal theta rhythm after localized de-afferentation of serotoninergic fibers. Brain Research, 1980, 200, 259-269.	1.1	90
270	Structural and functional restoration by collateral sprouting of hippocampal 5-HT axons. Nature, 1978, 274, 374-376.	13.7	127

#	Article	IF	Citations
271	British Foreign Policy, 1945-1973. American Political Science Review, 1977, 71, 410.	2.6	0
272	The Politics of Nuclear Proliferation. By George H. Quester. (Baltimore, Md.: The Johns Hopkins) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70	2.6	0
273	War and Politics, By Bernard Brodie. (New York: Macmillan, 1973. Pp. 496. $8.95.). American Political Science Review, 1975, 69, 731-732.	2.6	0
274	The Fortunes of the West: The Future of the Atlantic Nations.. Political Science Quarterly, 1974, 89, 458.	0.1	0
275	Multicoloured Britain. International Journal, 1968, 23, 520-530.	0.4	2